Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs.
Pharmacogenomics
; 18(12): 1143-1153, 2017 Aug.
Article
em En
| MEDLINE
| ID: mdl-28745583
ABSTRACT
AIM:
To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations. MATERIALS &METHODS:
A decision tree was used.RESULTS:
With a willingness-to-pay threshold of 20,000 and 80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of 1.30 and 1.95, respectively. When only genotyping high-risk populations, the maximum test price would be 5.03 and 7.55, respectively.CONCLUSION:
This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Farmacogenética
/
Inibidores da Enzima Conversora de Angiotensina
/
Fármacos Cardiovasculares
/
Angioedema
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Health_technology_assessment
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article